生命科学资讯

J&J praises new FDA guidance to speed development of multiple myeloma drugs

Johnson & Johnson brushes off MFN impact, sees strong growth for 2026

Tanabe pill delays blood disorder; enGene adds up to $100M from loans

IntraBio says rare disease drug passes Phase 3, will seek FDA approval

#JPM26: Regeneron, Lilly, Summit on rivals crowding into same targets

Exclusive: Claim Health raises $4.4M to help home care providers get paid

Fosun-funded Hygtia Therapeutics licenses Insilico’s NLRP3 inhibitor for Parkinson’s

Think Bioscience gets $55M to unearth new drug pockets

Government funding bill features PBM reforms, voucher reauthorization

EU Parliament adopts stricter drug stockpiling rules under Critical Medicines Act

Valneva withdraws chikungunya vaccine from US

Clinician groups ask court to overturn CDC's childhood vaccine overhaul

Aspect Bio takes Novo castoff therapies; Takeda trims US jobs

Teladoc’s mental health arm BetterHelp has quietly expanded the use of AI

2025 ended on high note with a buoyant Q4 for M&A, PIPEs and follow-ons

Pfizer to depart GSK's ViiV as Shionogi doubles its stake

J&J, Isomorphic sign research deal for AI-made molecules

GSK makes $2.2B deal for RAPT and its food allergy candidate

Exciva raises $59M Series B to fund Phase 2 test of Alzheimer’s agitation drug

JPM recap; Mirador raises $250M; Genentech’s PBM shift; and more